Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Treatment crawled time : 00:20 save search
EyePoint Pharmaceuticals Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration
Published: 2024-02-03 (Crawled : 00:20) - globenewswire.com
EYPT | News | $16.47 -6.26% -6.68% 1.1M
|
Health Technology
| Email alert
Add to watchlist
eyp-1901 macular treatment pharmaceuticals topline trial
Amylyx Pharmaceuticals Receives Negative CHMP Opinion on its Marketing Authorisation Application for AMX0035 for the Treatment of ALS in the European Union Following Re-Examination Process
Published: 2023-10-13 (Crawled : 00:20) - biospace.com/
AMLX A | $1.88 -3.59% -3.72% 1.4M
|
|
| O: -3.75%
H: 2.83%
C: 2.18%
amx0035 chmp als treatment pharmaceuticals application negative
Path for BrainStorm ALS Treatment Remains Rocky, Hope for Others on Horizon
Published: 2023-09-29 (Crawled : 00:20) - biospace.com/
FNCTF | News | $11.16 -20.84% 130
|
Communications
| Email alert
Add to watchlist
als hope treatment
Global Vitiligo Treatment Market 2023 - 2028: Ongoing Research and Advocacy Drive Progress
Published: 2023-09-01 (Crawled : 00:20) - prnewswire.com
CLVLY | $9.756 31.84% 15K
|
Professional, Scientific, and T...
| Email alert
Add to watchlist
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
| Email alert
Add to watchlist
CLVLF | $8.9 53.4% 2K
|
Health Technology
| Email alert
Add to watchlist
treatment ongoing research global market
Data of Deucrictibant for the On-Demand Treatment of HAE Attacks Presented at the EAACI Congress 2023
Published: 2023-06-10 (Crawled : 00:20) - globenewswire.com
PHVS | $21.1 -0.89% -0.9% 34K
|
| Email alert
Add to watchlist
treatment
Ocular Therapeutix™ Announces 12-Month Topline Data from Ongoing U.S.-Based Phase 1 Clinical Trial Evaluating OTX-TKI for Treatment of Wet AMD
Published: 2023-06-10 (Crawled : 00:20) - globenewswire.com
OCUL | News | $4.645 -7.1% -7.64% 3.9M
|
Health Technology
| Email alert
Add to watchlist
ocular treatment ongoing topline trial
Innovent Announces the Second Breakthrough Therapy Designation by NMPA for Olverembatinib for the Treatment of Patients with SDH-Deficient GIST
Published: 2023-06-02 (Crawled : 00:20) - prnewswire.com
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
| Email alert
Add to watchlist
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
| Email alert
Add to watchlist
treatment designation therapy
Global Addiction Treatment Market Report 2023: Sector to Reach $11.7 Billion by 2031 at a 6.1% CAGR
Published: 2023-05-26 (Crawled : 00:20) - prnewswire.com
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
| Email alert
Add to watchlist
NVSEF | News | $96.0 6.88% 52K
|
Health Technology
| Email alert
Add to watchlist
SYK | $336.85 0.58% 0.0% 1.5M
|
Health Technology
| Email alert
Add to watchlist
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
| Email alert
Add to watchlist
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
| Email alert
Add to watchlist
report reach treatment global market
Global Compressed Air Treatment Equipment Market Report 2023: Expansion of the Healthcare and Pharmaceutical Sectors Bolsters Growth
Published: 2023-05-27 (Crawled : 00:20) - prnewswire.com
PNR 4 | $78.99 0.66% 0.0% 2M
|
Producer Manufacturing
| Email alert
Add to watchlist
air report treatment expansion global growth market
Global Cellulite Treatment Global Market 2023-2030: Increasing Trend of Anti-Cellulite Massage Presents Opportunities
Published: 2023-05-19 (Crawled : 00:20) - prnewswire.com
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
| Email alert
Add to watchlist
ENDP | News | $0.2926 -9.6%
|
Health Technology
| Email alert
Add to watchlist
ENDPQ | News | $0.0007 -50.0% 1K
|
n/a
| Email alert
Add to watchlist
treatment global market
U.S. FDA Approves VRAYLAR® (cariprazine) as an Adjunctive Treatment for Major Depressive Disorder
Published: 2022-12-16 (Crawled : 00:20) - prnewswire.com
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
| Email alert
Add to watchlist
vraylar treatment fda major depressive disorder
Centessa Pharmaceuticals Announces Additional 18-Months of Continued Treatment Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia
Published: 2022-12-10 (Crawled : 00:20) - globenewswire.com
CNTA | News | $9.475 0.8% 0.79% 2.2M
|
Manufacturing
| Email alert
Add to watchlist
treatment pharmaceuticals extension study phase 2b
Intellia Therapeutics Presents New Interim Data from First-in-Human Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the American College of Allergy, Asthma & Immunology 2022 Annual Scientific Meeting
Published: 2022-11-12 (Crawled : 00:20) - globenewswire.com
NTLA | $21.16 -1.72% -1.75% 860K
|
Health Technology
| Email alert
Add to watchlist
ntla-2002 treatment immunology meeting therapeutics study hereditary angioedema
Everest Medicines Announces Approval of XERAVA® in Hong Kong for the Treatment of Complicated Intra-Abdominal Infections
Published: 2022-10-08 (Crawled : 00:20) - prnewswire.com
LJPC | $6.22 0.0%
|
Health Technology
| Email alert
Add to watchlist
xerava treatment infections approval
Citrus Flavonoids As A Prediabetes Treatment
Published: 2022-09-16 (Crawled : 00:20) - limoneira.com
FNCTF | News | $11.16 -20.84% 130
|
Communications
| Email alert
Add to watchlist
LMNR 4 | $20.105 2.0% 1.96% 41K
|
Process Industries
| Email alert
Add to watchlist
treatment citrus
Myovant Sciences Announces European Commission Approval for ORGOVYX® (relugolix) for the Treatment of Advanced Hormone-Sensitive Prostate Cancer
Published: 2022-04-29 (Crawled : 00:20) - globenewswire.com
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
| Email alert
Add to watchlist
orgovyx treatment approval cancer prostate cancer
Supernus Announces FDA Approval of Qelbree® for the Treatment of ADHD in Adults
Published: 2022-04-30 (Crawled : 00:20) - globenewswire.com
SUPN | $30.26 1.04% 1.02% 200K
|
Health Technology
| Email alert
Add to watchlist
qelbree treatment fda adhd approval
ObsEva Provides Update on EU Marketing Authorisation Process for Linzagolix, an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
Published: 2022-02-04 (Crawled : 00:20) - biospace.com/
OBSV | $0.1018 -15.52% -18.95% 8.2M
|
Health Technology
|
| O: -2.14%
H: 0.0%
C: 0.0%
treatment uterine fibroids linzagolix
CTI BioPharma Announces Topline Data from Final Analysis of the PRE-VENT Clinical Trial Evaluating Pacritinib as a Treatment for Severe COVID-19
Published: 2021-10-01 (Crawled : 00:20) - biospace.com/
CTIC | $9.09 0.05% 11M
|
Health Technology
|
| O: 1.69%
H: 0.0%
C: 0.0%
covid treatment biopharma topline trial
REGENXBIO Presents Positive Initial Data from Phase II AAVIATE® Trial of RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery and Provides Trial Update at Retina Society 54th Annual Scientific Meeting
Published: 2021-10-01 (Crawled : 00:20) - biospace.com/
RGNX | $16.05 0.94% 0.93% 350K
|
Health Technology
|
| O: 0.5%
H: 0.0%
C: 0.0%
CLSD | News P | $1.33 -2.92% -3.01% 200K
|
Health Technology
|
| O: -1.5%
H: 0.0%
C: 0.0%
treatment positive retina liver trial
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.